Tech Company Financing Transactions
Cloverleaf Bio Funding Round
4BIO Capital, AbbVie Biotech Ventures and Boehringer Ingelheim Venture Fund participated in a $33 million Seed funding round for Cloverleaf Bio. This venture round was announced by the company on 9/8/2026.
Transaction Overview
Company Name
Announced On
9/8/2026
Transaction Type
Venture Equity
Amount
$33,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to advance its two lead programs: an inhibitory tRNA asset targeting hepatocellular carcinoma through early clinical testing and an antibody-tRNA conjugate (ATC) asset targeting colorectal cancer through preclinical development.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Undisclosed
New Haven, CT Undisclosed
USA
New Haven, CT Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Cloverleaf is developing a new class of RNA therapeutics to revolutionize cancer therapy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Austin Draycott
Browse more venture capital transactions:
Prev: 9/8/2026: Dawraty venture capital transaction
Next: 9/8/2026: SCAIT venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to document every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs